Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
KPTI Karyopharm Therapeutics Inc. daily Stock Chart
KPTI [NASD]
Karyopharm Therapeutics Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-3.23 Insider Own1.90% Shs Outstand73.66M Perf Week-8.99%
Market Cap1.31B Forward P/E- EPS next Y-1.15 Insider Trans-20.44% Shs Float63.16M Perf Month-31.78%
Income-199.60M PEG- EPS next Q-0.69 Inst Own88.80% Short Float19.61% Perf Quarter-2.20%
Sales40.90M P/S32.09 EPS this Y-2.60% Inst Trans-0.03% Short Ratio7.04 Perf Half Y72.67%
Book/sh0.78 P/B22.85 EPS next Y48.90% ROA-71.40% Target Price33.25 Perf Year209.37%
Cash/sh3.56 P/C5.01 EPS next 5Y- ROE-254.70% 52W Range4.26 - 29.61 Perf YTD-7.04%
Dividend- P/FCF- EPS past 5Y-5.80% ROI-118.50% 52W High-39.82% Beta1.68
Dividend %- Quick Ratio6.00 Sales past 5Y182.10% Gross Margin94.10% 52W Low318.31% ATR2.52
Employees347 Current Ratio6.00 Sales Q/Q8684.50% Oper. Margin- RSI (14)45.07 Volatility7.83% 13.41%
OptionableYes Debt/Eq2.21 EPS Q/Q20.50% Profit Margin- Rel Volume0.45 Prev Close18.09
ShortableYes LT Debt/Eq2.21 EarningsMay 14 BMO Payout- Avg Volume1.76M Price17.82
Recom1.70 SMA20-8.82% SMA50-3.37% SMA20030.58% Volume787,030 Change-1.49%
Mar-04-20Initiated Barclays Overweight $30
Jan-17-20Downgrade Wedbush Outperform → Neutral
Jul-23-19Upgrade JP Morgan Neutral → Overweight $8 → $16
Jul-05-19Reiterated Robert W. Baird Outperform $15 → $25
Jul-05-19Reiterated H.C. Wainwright Buy $29 → $32
Mar-01-19Downgrade JP Morgan Overweight → Neutral $21 → $7
Feb-28-19Reiterated BofA/Merrill Underperform $15 → $5
Feb-27-19Downgrade BofA/Merrill Neutral → Underperform $15 → $5
Jan-03-19Upgrade BofA/Merrill Underperform → Neutral
Dec-03-18Initiated B. Riley FBR Buy $23
Nov-09-18Upgrade Wedbush Neutral → Outperform $19
May-24-18Downgrade Wedbush Outperform → Neutral $20 → $19
Apr-02-18Resumed Leerink Partners Outperform $19
Nov-15-17Resumed H.C. Wainwright Buy $23
Sep-15-17Initiated RBC Capital Mkts Outperform $14
Sep-08-16Reiterated H.C. Wainwright Buy $15 → $16
Aug-30-16Upgrade Jefferies Hold → Buy
Aug-18-16Initiated H.C. Wainwright Buy $15
Jun-28-16Initiated Robert W. Baird Outperform $16
May-27-16Initiated Raymond James Outperform $13
Apr-01-20 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.99%
Mar-24-20 04:23PM  Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch +10.78%
Mar-19-20 08:57AM  Karyopharm (KPTI): Strong Industry, Solid Earnings Estimate Revisions Zacks +18.09%
Mar-17-20 04:05PM  Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +7.03%
Mar-12-20 07:00AM  Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer GlobeNewswire -12.85%
Mar-09-20 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -13.03%
Mar-06-20 04:05PM  Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-03-20 06:36PM  Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -10.98%
09:53AM  Company News for Mar 3, 2020 Zacks
07:51AM  The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More Benzinga
Mar-02-20 04:11PM  This Biotech Stock Broke Out As A Cancer Drug 'Transforms' Its Story Investor's Business Daily +69.65%
04:01PM  Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
12:57PM  Karyopharm's stock jumps on trial results for multiple myeloma combo candidate MarketWatch
07:00AM  Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy GlobeNewswire
Feb-28-20 07:00AM  Karyopharm Appoints Richard Paulson to its Board of Directors GlobeNewswire +6.24%
Feb-27-20 08:43AM  Do Options Traders Know Something About Karyopharm (KPTI) Stock We Don't? Zacks +6.95%
Feb-20-20 09:16PM  Edited Transcript of KPTI earnings conference call or presentation 13-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-19-20 08:00AM  U.S. Food and Drug Administration Accepts Karyopharms Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma GlobeNewswire
Feb-18-20 07:03AM  Is Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Salary Justified? Simply Wall St. +6.24%
07:00AM  Karyopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-13-20 08:35AM  Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:00AM  Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress GlobeNewswire
Feb-11-20 07:00AM  Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel GlobeNewswire
Feb-10-20 10:20AM  What's in Store for Acorda (ACOR) This Earnings Season? Zacks
10:13AM  What's in Store for Ironwood (IRWD) This Earnings Season? Zacks
Feb-06-20 07:00AM  Karyopharm to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020 GlobeNewswire
Feb-03-20 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-22-20 09:33AM  3 Healthcare Stocks With Important Catalysts in Q1 TipRanks
Jan-20-20 08:45AM  Options Traders Expect Huge Moves in Karyopharm (KPTI) Stock Zacks
Jan-15-20 09:56AM  BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU Zacks
Jan-13-20 05:03PM  Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I Zacks -6.18%
09:13AM  Top Ranked Momentum Stocks to Buy for January 13th Zacks
07:00AM  Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update GlobeNewswire
Jan-08-20 11:23AM  Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics Zacks
Jan-07-20 09:03AM  5 Stocks With Recent Price Strength for Spectacular Returns Zacks
07:00AM  Karyopharm to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-20 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-24-19 07:24AM  The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga
Dec-23-19 07:38AM  Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma GlobeNewswire
Dec-20-19 07:15AM  Is Karyopharm Therapeutics (NASDAQ:KPTI) Weighed On By Its Debt Load? Simply Wall St.
Dec-19-19 10:27AM  One particular field of drug development could dominate M&A in 2020 American City Business Journals
Dec-13-19 03:26PM  Hedge Funds Dropped The Ball On Karyopharm Therapeutics Inc (KPTI) Insider Monkey
Dec-09-19 07:25AM  There's A Really Good Chance You Missed One Of The Year's Best ETFs Benzinga
Dec-08-19 09:00AM  Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting GlobeNewswire
Dec-07-19 09:00AM  Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting GlobeNewswire
Dec-03-19 01:48PM  The Best-Performing ETF Has a Winning Strategy, But Just $29 Million Bloomberg
Dec-02-19 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-19 10:00AM  Are You Looking for a Top Momentum Pick? Why Karyopharm Therapeutics (KPTI) is a Great Choice Zacks
Nov-09-19 10:25PM  Edited Transcript of KPTI earnings conference call or presentation 4-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-06-19 10:12AM  Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting GlobeNewswire
08:52AM  Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4% Zacks
03:40AM  3 Names Making the Case That Investing in Small Biotech Is Never Dull TheStreet.com
Nov-05-19 06:53AM  The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga +6.38%
Nov-04-19 11:28AM  Karyopharm exceeds analyst expectations for first cancer drug launch Reuters +6.22%
08:25AM  Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM  Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress GlobeNewswire
Nov-03-19 10:51AM  The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight Benzinga
Nov-01-19 04:58PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +7.18%
Oct-31-19 01:52PM  Did Hedge Funds Drop The Ball On Karyopharm Therapeutics Inc (KPTI)? Insider Monkey
Oct-30-19 03:30AM  SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Reminds Investors Karyopharm Therapeutics Inc. (KPTI) Sued for Misleading Shareholders; Karyopharm Shareholders Urged to Contact the Firm ACCESSWIRE
Oct-28-19 07:00AM  Karyopharm to Report Third Quarter 2019 Financial Results on November 4, 2019 GlobeNewswire
Oct-24-19 04:04PM  Shareholder Alert: Robbins Arroyo LLP Reminds Investors Karyopharm Therapeutics Inc. (KPTI) Sued for Misleading Shareholders Business Wire
Oct-21-19 11:42AM  If You Had Bought Karyopharm Therapeutics (NASDAQ:KPTI) Stock Five Years Ago, You'd Be Sitting On A 71% Loss, Today Simply Wall St.
Oct-04-19 10:00PM  Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm GlobeNewswire
Oct-01-19 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-23-19 12:30PM  CLASS ACTION UPDATE for MMM, KPTI and IFF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE -6.24%
10:20AM  FINAL DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 ACCESSWIRE
09:19AM  CLASS ACTION UPDATE for MMM, KPTI, GTT and VRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
08:45AM  MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-22-19 10:50PM  KARYOPHARM 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI GlobeNewswire
Sep-21-19 10:00AM  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm Business Wire
Sep-20-19 10:50PM  KARYOPHARM 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI Business Wire -5.21%
04:30PM  CLASS ACTION UPDATE for KPTI, CARB and OLLI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
03:00PM  INVESTOR ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 GlobeNewswire
01:30PM  SHAREHOLDER ALERT: LB KPTI CARB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
01:00PM  FINAL SEPT. 23 DEADLINE: GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action KPTI GlobeNewswire
10:30AM  KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm Newsfile
10:25AM  UPCOMING DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 ACCESSWIRE
10:25AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LB, KPTI and PS ACCESSWIRE
10:04AM  MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Sep-19-19 12:35PM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPTI, EGBN and TXT ACCESSWIRE
11:15AM  KPTI DEADLINE: Pawar Law Group Reminds Investors of September 23 Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI ACCESSWIRE
10:00AM  FINAL DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 PR Newswire
09:46AM  SHAREHOLDER ALERT: LB KPTI EGBN MDP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
06:25AM  CLASS ACTION DEADLINE UPDATE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines For Securities Violations: LB and KPTI ACCESSWIRE
Sep-18-19 10:50PM  SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
08:55PM  SHAREHOLDER ALERT: KPTI NGHC MNK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
08:21PM  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm PR Newswire
11:45AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of LB, KPTI and GTT ACCESSWIRE
10:49AM  UPCOMING DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 ACCESSWIRE
Sep-17-19 09:15PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, GTT and CAH ACCESSWIRE
07:44PM  Pomerantz Law Firm Announces the Filing of a Class Action against Karyopharm Therapeutics Inc. and Certain Officers KPTI GlobeNewswire
10:39AM  Karyopharm Signs $150M Royalty Agreement to Support Xpovio Zacks
09:58AM  CLASS ACTION UPDATE for NFLX, KPTI, GTT and EVH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Sep-16-19 10:50PM  SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire +7.43%
02:05PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, GVA and NTAP ACCESSWIRE
01:30PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. GlobeNewswire
11:10AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPTI, NGHC and GTT ACCESSWIRE
10:40AM  SHAREHOLDER ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 ACCESSWIRE
10:30AM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. GlobeNewswire
Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greene Barry EDirectorMar 13Option Exercise0.033,0301006,030Mar 17 05:35 PM
Kauffman MichaelChief Executive OfficerMar 10Option Exercise4.7510,00047,520565,122Mar 11 07:07 PM
Shacham SharonPresident & CSOMar 10Option Exercise4.7510,00047,520565,122Mar 11 07:10 PM
Shacham SharonPresident & CSOMar 10Sale22.2210,000222,186555,122Mar 11 07:10 PM
Kauffman MichaelChief Executive OfficerMar 10Sale22.2210,000222,186555,122Mar 11 07:07 PM
Kauffman MichaelChief Executive OfficerMar 09Option Exercise4.7510,00047,520766,489Mar 11 07:07 PM
Shacham SharonPresident & CSOMar 09Option Exercise4.7510,00047,520766,489Mar 11 07:10 PM
Shacham SharonPresident & CSOMar 09Sale22.5210,000225,195756,489Mar 11 07:10 PM
Kauffman MichaelChief Executive OfficerMar 09Sale22.5210,000225,195756,489Mar 11 07:07 PM
Mirza Mansoor RazaDirectorMar 02Option Exercise8.065,00040,3005,000Mar 04 06:51 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryMar 02Option Exercise10.3926,500275,33536,867Mar 04 08:33 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryMar 02Sale25.3726,500672,27910,367Mar 04 08:33 PM
Mirza Mansoor RazaDirectorMar 02Sale23.505,000117,5000Mar 04 06:51 PM
Frenkel RanChief Dev Operations OfficerFeb 19Sale16.482,97549,03436,066Feb 21 05:57 PM
Shah JatinEVP, Chief Medical OfficerFeb 19Sale16.481,37522,66340,759Feb 21 05:58 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryFeb 19Sale16.482,96148,80310,367Feb 21 05:55 PM
Shacham SharonPresident & CSOFeb 19Sale16.488,817145,321555,122Feb 21 05:54 PM
Shacham SharonPresident & CSOFeb 19Sale16.488,817145,321756,489Feb 21 05:54 PM
Kauffman MichaelChief Executive OfficerFeb 19Sale16.488,817145,321756,489Feb 21 05:53 PM
Kauffman MichaelChief Executive OfficerFeb 19Sale16.488,817145,321555,122Feb 21 05:53 PM
Kauffman MichaelChief Executive OfficerFeb 11Option Exercise4.7510,00047,520552,139Feb 12 04:20 PM
Shacham SharonPresident & CSOFeb 11Option Exercise4.7510,00047,520552,139Feb 12 04:21 PM
Shacham SharonPresident & CSOFeb 11Sale17.4310,000174,294542,139Feb 12 04:21 PM
Kauffman MichaelChief Executive OfficerFeb 11Sale17.4310,000174,294542,139Feb 12 04:20 PM
Kauffman MichaelChief Executive OfficerFeb 10Option Exercise4.7510,00047,520753,506Feb 12 04:20 PM
Shacham SharonPresident & CSOFeb 10Option Exercise4.7510,00047,520753,506Feb 12 04:21 PM
Shacham SharonPresident & CSOFeb 10Sale16.9310,000169,327743,506Feb 12 04:21 PM
Kauffman MichaelChief Executive OfficerFeb 10Sale16.9310,000169,327743,506Feb 12 04:20 PM
Kauffman MichaelChief Executive OfficerJan 09Option Exercise4.7510,00047,520552,139Jan 10 05:07 PM
Shacham SharonPresident & CSOJan 09Option Exercise4.7510,00047,520552,139Jan 10 05:04 PM
Mirza Mansoor RazaDirectorJan 09Option Exercise8.062,05616,5712,056Jan 13 05:02 PM
Mirza Mansoor RazaDirectorJan 09Sale20.002,05641,1200Jan 13 05:02 PM
Shacham SharonPresident & CSOJan 09Sale19.1910,000191,880542,139Jan 10 05:04 PM
Kauffman MichaelChief Executive OfficerJan 09Sale19.1910,000191,880542,139Jan 10 05:07 PM
Shacham SharonPresident & CSOJan 08Option Exercise4.7510,00047,520753,506Jan 10 05:04 PM
Kauffman MichaelChief Executive OfficerJan 08Option Exercise4.7510,00047,520753,506Jan 10 05:07 PM
Kauffman MichaelChief Executive OfficerJan 08Sale18.5710,000185,705743,506Jan 10 05:07 PM
Shacham SharonPresident & CSOJan 08Sale18.5710,000185,705743,506Jan 10 05:04 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryDec 27Option Exercise10.395,00051,9508,653Dec 31 09:06 AM
Mirza Mansoor RazaDirectorDec 27Option Exercise8.062,94423,7292,944Dec 31 09:15 AM
Mirza Mansoor RazaDirectorDec 27Sale20.002,94458,8800Dec 31 09:15 AM
Primiano Christopher BrettEVP, CBO, GC & SecretaryDec 27Sale20.005,000100,0003,653Dec 31 09:06 AM
Mirza Mansoor RazaDirectorDec 18Option Exercise1.4912,12118,00012,121Dec 20 04:04 PM
Mirza Mansoor RazaDirectorDec 18Sale17.1812,121208,2360Dec 20 04:04 PM
Shacham SharonPresident & CSODec 10Option Exercise4.7510,00047,520539,767Dec 11 05:21 PM
Kauffman MichaelChief Executive OfficerDec 10Option Exercise4.7510,00047,520539,767Dec 11 05:24 PM
Kauffman MichaelChief Executive OfficerDec 10Sale15.9910,000159,896529,767Dec 11 05:24 PM
Shacham SharonPresident & CSODec 10Sale15.9910,000159,896529,767Dec 11 05:21 PM
Mirza Mansoor RazaDirectorDec 09Option Exercise5.6410,34258,36010,342Dec 11 05:26 PM
Shacham SharonPresident & CSODec 09Option Exercise4.7510,00047,520741,134Dec 11 05:21 PM
Kauffman MichaelChief Executive OfficerDec 09Option Exercise4.7510,00047,520741,134Dec 11 05:24 PM
Kauffman MichaelChief Executive OfficerDec 09Sale17.0210,000170,210731,134Dec 11 05:24 PM
Shacham SharonPresident & CSODec 09Sale17.0210,000170,210731,134Dec 11 05:21 PM
Mirza Mansoor RazaDirectorDec 09Sale17.0210,342176,0340Dec 11 05:26 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryDec 06Option Exercise8.4710,00084,65016,653Dec 10 05:18 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryDec 06Sale17.4513,000226,9083,653Dec 10 05:18 PM
Shacham SharonPresident & CSONov 11Option Exercise4.7510,00047,520539,767Nov 12 04:34 PM
Kauffman MichaelChief Executive OfficerNov 11Option Exercise4.7510,00047,520539,767Nov 12 04:39 PM
Shacham SharonPresident & CSONov 11Sale14.7610,000147,610529,767Nov 12 04:34 PM
Kauffman MichaelChief Executive OfficerNov 11Sale14.7610,000147,610529,767Nov 12 04:39 PM
Kauffman MichaelChief Executive OfficerNov 08Option Exercise4.7510,00047,520741,134Nov 12 04:39 PM
Shacham SharonPresident & CSONov 08Option Exercise4.7510,00047,520741,134Nov 12 04:34 PM
Kauffman MichaelChief Executive OfficerNov 08Sale14.6310,000146,254731,134Nov 12 04:39 PM
Shacham SharonPresident & CSONov 08Sale14.6310,000146,254731,134Nov 12 04:34 PM
Kauffman MichaelChief Executive OfficerNov 01Option Exercise4.7510,00047,520741,134Nov 05 04:08 PM
Kauffman MichaelChief Executive OfficerNov 01Option Exercise4.7510,00047,520539,767Nov 05 04:08 PM
Shacham SharonPresident & CSONov 01Option Exercise4.7510,00047,520539,767Nov 05 04:10 PM
Shacham SharonPresident & CSONov 01Option Exercise4.7510,00047,520741,134Nov 05 04:10 PM
Shacham SharonPresident & CSONov 01Sale12.0010,000120,000529,767Nov 05 04:10 PM
Shacham SharonPresident & CSONov 01Sale12.0010,000120,000731,134Nov 05 04:10 PM
Kauffman MichaelChief Executive OfficerNov 01Sale12.0010,000120,000731,134Nov 05 04:08 PM
Kauffman MichaelChief Executive OfficerNov 01Sale12.0010,000120,000529,767Nov 05 04:08 PM
Kauffman MichaelChief Executive OfficerSep 16Option Exercise4.7510,00047,520741,134Sep 17 04:56 PM
Kauffman MichaelChief Executive OfficerSep 16Option Exercise4.7510,00047,520539,767Sep 17 04:56 PM
Shacham SharonPresident & CSOSep 16Option Exercise4.7510,00047,520539,767Sep 17 04:54 PM
Shacham SharonPresident & CSOSep 16Option Exercise4.7510,00047,520741,134Sep 17 04:54 PM
Kauffman MichaelChief Executive OfficerSep 16Sale12.0010,000120,000731,134Sep 17 04:56 PM
Kauffman MichaelChief Executive OfficerSep 16Sale12.0010,000120,000529,767Sep 17 04:56 PM
Shacham SharonPresident & CSOSep 16Sale12.0010,000120,000529,767Sep 17 04:54 PM
Shacham SharonPresident & CSOSep 16Sale12.0010,000120,000731,134Sep 17 04:54 PM
open in yahoo | open in reuters | open in google